Published in Vaccine Weekly, August 9th, 1999
The results of the Phase II efficacy trial suggests that the two-dose oral rotavirus vaccine should be helpful in the prevention of rotavirus disease in young children. The clinical investigators reported that the vaccine provided those treated with nearly 90 percent protection from disease.
David Bernstein, MD, the lead investigator at the Cincinnati Children's Hospital Medical Center, in association with his colleagues at The Johns Hopkins University...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly